Skip to NavigationSkip to content

manufacturing

Avara Avlon falls into administration putting 270 Bristol jobs at risk

Bristol-based pharma firm Avara Avlon Pharmaceuticals has fallen into administration putting the jobs of all 270 of its staff at risk.

The contract development and manufacturing organisation (CDMO) is hoping to sell facilities in Avonmouth a suburb of Bristol, which it bought from AstraZeneca in 2016.

Irish Pfizer employees to launch industrial action ballot over pensions scheme

Pfizer employees have rejected a Labour Court recommendation regarding their pension scheme, opting to initiate a ballot over potential industrial action instead.

As many as 900 workers at Pfizer’s operations in Ireland will take part in the ballot which will determine what happens next.

The decision comes after Pfizer sought to switch 900 of its employees from pension schemes that offer workers a proportion of their salary on retirement to a new plan which would not offer this guarantee.  

Boehringer expands manufacturing facility in Shanghai

German firm Boehringer Ingelheim has expanded the capacity of its commercial manufacturing site for biologics in Shanghai, China.

The expansion will see the installation of an additional bioreactor into the company’s OASIS Shanghai facility.

“We are fully committed to our biopharmaceutical contract manufacturing business in China and it is our utmost goal to serve our customers and their patients with high quality medicines in China and in the global market’, said Prof Buecheler, Head of Biopharmaceutical Business Unit at Boehringer Ingelheim.

Sun Pharma's New Jersey manufacturing overhaul puts 96 jobs at risk

Indian pharma firm Sun Pharma has announced it is to combine its New Jersey manufacturing operations in a bid to “improve cost efficiencies, it has emerged – a move which puts almost 100 jobs at risk.

Specifically, the company plans to relocate operations at its facility in Cranbury to its site in New Brunswick, which will threaten 96 positions. The firm’s intention was confirmed in a WARN notice published by the New Jersey Department of Labor and Workforce Development

GSK veteran Dave Tudor joins MMIC in Scotland

Published on: 09/11/18

GlaxoSmithKline veteran, Dave Tudor, is set to take on the role of Managing Director of the Medicines Manufacturing Innovation Centre (MMIC), a new manufacturing centre designed to increase the speed and cost effectiveness of the process through which medicines are brought to market. The facility is set to be built in Renfrewshire, Scotland over the next two years.

GSK opens £54m API plant in Montrose, Scotland

British multinational GlaxoSmithKline has opened an API manufacturing plant in Montrose Scotland for its Ellipta respiratory medicines.

The new facility will work alongside the company’s site in Singapore to provide API’s for a range of respiratory drugs. The new plant represents a £54 million investment from the London-headquartered company.

However the highly automated facility is not expected to create a large number of jobs.

Top Ten most popular articles on Pharmafile.com this week

Politics played a big role in pharma this week after Trump introduced legislation aimed at reducing the price of drugs. The effectiveness of trust-busting biosimilar bill in bring the medicines to market may be an interesting development over the coming year. Meanwhile the UK government came into question after researchers were denied visas.

Novartis cuts more than 2500 jobs in Switzerland and the UK

Swiss multinational Novartis are set to cut thousands of jobs across Europe in an effort to boost profitability. The move comes as part of a major restructuring which will take place over the next four years.

The multibillion pound drugmaker announced today that they are culling 2,200 employees from their 13,000 person strong Swiss workforce, while news got out that a further 400 workers are set to lose their jobs in Grimsby in the North of England.

Top Ten most popular articles on Pharmafile.com this week

Manufacturing took a hit this week as Novo Nordisk announced the loss of 400 jobs while Novartis made the move from Arnhem to Amsterdam affecting another 400 jobs in the Netherlands. On top of all that Hurricane Florence shut down manufacturing plants in the American South as storms battered to Carolina coast forcing production to halt and wait out the storm.

Sanofi join AstraZeneca and MSD in stockpiling medicines, 1800 jobs at risk

French multinational Sanofi have begun stockpiling drugs in preparation for a no-deal Brexit.

The company will join AstraZeneca and MSD in making arrangements to increase its stockpile of medicines in preparation for an abrupt exit from the European Union. The French drug maker is set to increase its supplies to allow for an additional ten weeks of disruption as it seeks to build up 14 weeks’ worth of medical supplies.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches